ID   MK11_HUMAN              Reviewed;         364 AA.
AC   Q15759; A8K730; B0LPG1; B7Z630; E7ETQ1; L7RT27; O00284; O15472;
AC   Q2XNF2;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-2007, sequence version 2.
DT   15-MAR-2017, entry version 181.
DE   RecName: Full=Mitogen-activated protein kinase 11;
DE            Short=MAP kinase 11;
DE            Short=MAPK 11;
DE            EC=2.7.11.24;
DE   AltName: Full=Mitogen-activated protein kinase p38 beta;
DE            Short=MAP kinase p38 beta;
DE            Short=p38b;
DE   AltName: Full=Stress-activated protein kinase 2b;
DE            Short=SAPK2b;
DE   AltName: Full=p38-2;
GN   Name=MAPK11; Synonyms=PRKM11, SAPK2, SAPK2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=8663524; DOI=10.1074/jbc.271.30.17920;
RA   Jiang Y., Chen C., Li Z., Guo W., Gegner J.A., Lin S., Han J.;
RT   "Characterization of the structure and function of a new mitogen-
RT   activated protein kinase (p38beta).";
RL   J. Biol. Chem. 271:17920-17926(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Jiang Y., Han J.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9207191; DOI=10.1006/bbrc.1997.6849;
RA   Kumar S., McDonnell P.C., Gum R.J., Hand A.T., Lee J.C., Young P.R.;
RT   "Novel homologues of CSBP/p38 MAP kinase: activation, substrate
RT   specificity and sensitivity to inhibition by pyridinyl imidazoles.";
RL   Biochem. Biophys. Res. Commun. 235:533-538(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN PHOSPHORYLATION OF
RP   ATF2; ELK1 AND MBP, AND ENZYME REGULATION.
RC   TISSUE=Brain;
RX   PubMed=9430721; DOI=10.1074/jbc.273.3.1741;
RA   Enslen H., Raingeaud J., Davis R.J.;
RT   "Selective activation of p38 mitogen-activated protein (MAP) kinase
RT   isoforms by the MAP kinase kinases MKK3 and MKK6.";
RL   J. Biol. Chem. 273:1741-1748(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ENZYME REGULATION.
RX   PubMed=9218798; DOI=10.1093/emboj/16.12.3563;
RA   Goedert M., Cuenda A., Craxton M., Jakes R., Cohen P.;
RT   "Activation of the novel stress-activated protein kinase SAPK4 by
RT   cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison
RT   of its substrate specificity with that of other SAP kinases.";
RL   EMBO J. 16:3563-3571(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9235954; DOI=10.1074/jbc.272.31.19509;
RA   Stein B., Yang M.X., Young D.B., Janknecht R., Hunter T., Murray B.W.,
RA   Barbosa M.S.;
RT   "p38-2, a novel mitogen-activated protein kinase with distinct
RT   properties.";
RL   J. Biol. Chem. 272:19509-19517(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HIS-275.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (AUG-2012) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   FUNCTION IN ACTIVATION OF RPS6KA5/MSK1.
RX   PubMed=9687510; DOI=10.1093/emboj/17.15.4426;
RA   Deak M., Clifton A.D., Lucocq J.M., Alessi D.R.;
RT   "Mitogen- and stress-activated protein kinase-1 (MSK1) is directly
RT   activated by MAPK and SAPK2/p38, and may mediate activation of CREB.";
RL   EMBO J. 17:4426-4441(1998).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF MEF2A AND MEF2C.
RX   PubMed=10330143; DOI=10.1128/MCB.19.6.4028;
RA   Yang S.-H., Galanis A., Sharrocks A.D.;
RT   "Targeting of p38 mitogen-activated protein kinases to MEF2
RT   transcription factors.";
RL   Mol. Cell. Biol. 19:4028-4038(1999).
RN   [16]
RP   INTERACTION WITH DUSP16, AND ENZYME REGULATION.
RX   PubMed=11359773; DOI=10.1074/jbc.M101981200;
RA   Tanoue T., Yamamoto T., Maeda R., Nishida E.;
RT   "A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and
RT   p38 alpha and beta MAPKs.";
RL   J. Biol. Chem. 276:26629-26639(2001).
RN   [17]
RP   FUNCTION AS MKNK2 KINASE.
RX   PubMed=11154262; DOI=10.1128/MCB.21.3.743-754.2001;
RA   Scheper G.C., Morrice N.A., Kleijn M., Proud C.G.;
RT   "The mitogen-activated protein kinase signal-integrating kinase Mnk2
RT   is a eukaryotic initiation factor 4E kinase with high levels of basal
RT   activity in mammalian cells.";
RL   Mol. Cell. Biol. 21:743-754(2001).
RN   [18]
RP   INTERACTION WITH HDAC3, PHOSPHORYLATION, ENZYME REGULATION, AND
RP   FUNCTION IN ATF2 ACTIVATION.
RX   PubMed=15356147; DOI=10.4049/jimmunol.173.6.3979;
RA   Mahlknecht U., Will J., Varin A., Hoelzer D., Herbein G.;
RT   "Histone deacetylase 3, a class I histone deacetylase, suppresses
RT   MAPK11-mediated activating transcription factor-2 activation and
RT   represses TNF gene expression.";
RL   J. Immunol. 173:3979-3990(2004).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=12452429; DOI=10.1515/BC.2002.173;
RA   Shi Y., Gaestel M.;
RT   "In the cellular garden of forking paths: how p38 MAPKs signal for
RT   downstream assistance.";
RL   Biol. Chem. 383:1519-1536(2002).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=20626350; DOI=10.1042/BJ20100323;
RA   Cuadrado A., Nebreda A.R.;
RT   "Mechanisms and functions of p38 MAPK signalling.";
RL   Biochem. J. 429:403-417(2010).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=19622861; DOI=10.1107/S090744490901600X;
RA   Patel S.B., Cameron P.M., O'Keefe S.J., Frantz-Wattley B.,
RA   Thompson J., O'Neill E.A., Tennis T., Liu L., Becker J.W., Scapin G.;
RT   "The three-dimensional structure of MAP kinase p38beta: different
RT   features of the ATP-binding site in p38beta compared with p38alpha.";
RL   Acta Crystallogr. D 65:777-785(2009).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-221 AND HIS-275.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. MAPK11 is
CC       one of the four p38 MAPKs which play an important role in the
CC       cascades of cellular responses evoked by extracellular stimuli
CC       such as proinflammatory cytokines or physical stress leading to
CC       direct activation of transcription factors. Accordingly, p38 MAPKs
CC       phosphorylate a broad range of proteins and it has been estimated
CC       that they may have approximately 200 to 300 substrates each.
CC       MAPK11 functions are mostly redundant with those of MAPK14. Some
CC       of the targets are downstream kinases which are activated through
CC       phosphorylation and further phosphorylate additional targets.
CC       RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and
CC       activate transcription factors such as CREB1, ATF1, the NF-kappa-B
CC       isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate
CC       histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and
CC       RPS6KA4/MSK2 play important roles in the rapid induction of
CC       immediate-early genes in response to stress or mitogenic stimuli,
CC       either by inducing chromatin remodeling or by recruiting the
CC       transcription machinery. On the other hand, two other kinase
CC       targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control
CC       of gene expression mostly at the post-transcriptional level, by
CC       phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by
CC       regulating EEF2K, which is important for the elongation of mRNA
CC       during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases
CC       activated by p38 MAPKs, regulate protein synthesis by
CC       phosphorylating the initiation factor EIF4E2. In the cytoplasm,
CC       the p38 MAPK pathway is an important regulator of protein
CC       turnover. For example, CFLAR is an inhibitor of TNF-induced
CC       apoptosis whose proteasome-mediated degradation is regulated by
CC       p38 MAPK phosphorylation. Ectodomain shedding of transmembrane
CC       proteins is regulated by p38 MAPKs as well. In response to
CC       inflammatory stimuli, p38 MAPKs phosphorylate the membrane-
CC       associated metalloprotease ADAM17. Such phosphorylation is
CC       required for ADAM17-mediated ectodomain shedding of TGF-alpha
CC       family ligands, which results in the activation of EGFR signaling
CC       and cell proliferation. Additional examples of p38 MAPK substrates
CC       are the FGFR1. FGFR1 can be translocated from the extracellular
CC       space into the cytosol and nucleus of target cells, and regulates
CC       processes such as rRNA synthesis and cell growth. FGFR1
CC       translocation requires p38 MAPK activation. In the nucleus, many
CC       transcription factors are phosphorylated and activated by p38
CC       MAPKs in response to different stimuli. Classical examples include
CC       ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and
CC       MEF2A. The p38 MAPKs are emerging as important modulators of gene
CC       expression by regulating chromatin modifiers and remodelers. The
CC       promoters of several genes involved in the inflammatory response,
CC       such as IL6, IL8 and IL12B, display a p38 MAPK-dependent
CC       enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in
CC       LPS-stimulated myeloid cells. This phosphorylation enhances the
CC       accessibility of the cryptic NF-kappa-B-binding sites marking
CC       promoters for increased NF-kappa-B recruitment.
CC       {ECO:0000269|PubMed:10330143, ECO:0000269|PubMed:11154262,
CC       ECO:0000269|PubMed:15356147, ECO:0000269|PubMed:9430721,
CC       ECO:0000269|PubMed:9687510}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by phosphorylation on threonine and
CC       tyrosine by MAP2K3/MKK3, MAP2K4/MKK4 and MAP2K6/MKK6. MAP2K3/MKK3
CC       and MAP2K6/MKK6 are both essential for the activation of MAPK11
CC       induced by environmental stress. HDAC3 interacts directly and
CC       selectively with MAPK11 to repress ATF2 transcriptional activity,
CC       and regulate TNF gene expression in LPS-stimulated cells.
CC       Inhibited by SB203580 and pyridinyl-imidazole related compounds.
CC       {ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:15356147,
CC       ECO:0000269|PubMed:9218798, ECO:0000269|PubMed:9430721}.
CC   -!- SUBUNIT: Interacts with HDAC3 and DUSP16.
CC       {ECO:0000269|PubMed:11359773, ECO:0000269|PubMed:15356147,
CC       ECO:0000269|PubMed:19622861}.
CC   -!- INTERACTION:
CC       P04637:TP53; NbExp=2; IntAct=EBI-298304, EBI-366083;
CC       O43257:ZNHIT1; NbExp=2; IntAct=EBI-298304, EBI-347522;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15759-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15759-3; Sequence=VSP_055221, VSP_055222, VSP_055223;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highest levels in the brain and heart. Also
CC       expressed in the placenta, lung, liver, skeletal muscle, kidney
CC       and pancreas.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-180 and Tyr-182 by MAP2K3/MKK3,
CC       MAP2K4/MKK4 and MAP2K6/MKK6, which activates the enzyme.
CC       {ECO:0000269|PubMed:15356147}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mapk11/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U53442; AAB05036.1; -; mRNA.
DR   EMBL; AF001008; AAC51250.1; -; mRNA.
DR   EMBL; AF001174; AAC51373.1; -; mRNA.
DR   EMBL; AF031135; AAC12714.1; -; mRNA.
DR   EMBL; Y14440; CAA74792.1; -; mRNA.
DR   EMBL; U92268; AAB66313.1; -; mRNA.
DR   EMBL; CR456514; CAG30400.1; -; mRNA.
DR   EMBL; DQ279722; ABB72677.1; -; Genomic_DNA.
DR   EMBL; AK291845; BAF84534.1; -; mRNA.
DR   EMBL; AK299745; BAH13116.1; -; mRNA.
DR   EMBL; EU332851; ABY87540.1; -; Genomic_DNA.
DR   EMBL; JX512451; AGC09598.1; -; Genomic_DNA.
DR   EMBL; AL022328; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471138; EAW73524.1; -; Genomic_DNA.
DR   EMBL; CH471138; EAW73525.1; -; Genomic_DNA.
DR   EMBL; CH471138; EAW73526.1; -; Genomic_DNA.
DR   EMBL; BC027933; AAH27933.1; -; mRNA.
DR   CCDS; CCDS14090.1; -. [Q15759-1]
DR   PIR; G02524; G02524.
DR   PIR; JC5529; JC5529.
DR   RefSeq; NP_002742.3; NM_002751.6. [Q15759-1]
DR   UniGene; Hs.57732; -.
DR   PDB; 3GC8; X-ray; 2.40 A; A/B=1-364.
DR   PDB; 3GC9; X-ray; 2.05 A; A/B=1-364.
DR   PDB; 3GP0; X-ray; 1.90 A; A=5-350.
DR   PDBsum; 3GC8; -.
DR   PDBsum; 3GC9; -.
DR   PDBsum; 3GP0; -.
DR   ProteinModelPortal; Q15759; -.
DR   SMR; Q15759; -.
DR   BioGrid; 111586; 30.
DR   IntAct; Q15759; 21.
DR   MINT; MINT-3032032; -.
DR   STRING; 9606.ENSP00000333685; -.
DR   BindingDB; Q15759; -.
DR   ChEMBL; CHEMBL3961; -.
DR   DrugBank; DB05157; KC706.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1500; -.
DR   iPTMnet; Q15759; -.
DR   PhosphoSitePlus; Q15759; -.
DR   BioMuta; MAPK11; -.
DR   DMDM; 134047835; -.
DR   EPD; Q15759; -.
DR   PaxDb; Q15759; -.
DR   PeptideAtlas; Q15759; -.
DR   PRIDE; Q15759; -.
DR   DNASU; 5600; -.
DR   Ensembl; ENST00000330651; ENSP00000333685; ENSG00000185386. [Q15759-1]
DR   Ensembl; ENST00000395764; ENSP00000379113; ENSG00000185386. [Q15759-1]
DR   GeneID; 5600; -.
DR   KEGG; hsa:5600; -.
DR   UCSC; uc003bkr.4; human. [Q15759-1]
DR   CTD; 5600; -.
DR   DisGeNET; 5600; -.
DR   GeneCards; MAPK11; -.
DR   HGNC; HGNC:6873; MAPK11.
DR   HPA; CAB012961; -.
DR   HPA; HPA045069; -.
DR   MIM; 602898; gene.
DR   neXtProt; NX_Q15759; -.
DR   OpenTargets; ENSG00000185386; -.
DR   PharmGKB; PA30618; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   eggNOG; ENOG410XNY0; LUCA.
DR   GeneTree; ENSGT00550000074271; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; Q15759; -.
DR   KO; K04441; -.
DR   OMA; ISFKPPD; -.
DR   OrthoDB; EOG091G08QL; -.
DR   PhylomeDB; Q15759; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-198753; ERK/MAPK targets.
DR   Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-375170; CDO in myogenesis.
DR   Reactome; R-HSA-376172; DSCAM interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-HSA-450604; KSRP (KHSRP) binds and destabilizes mRNA.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q15759; -.
DR   SIGNOR; Q15759; -.
DR   EvolutionaryTrace; Q15759; -.
DR   GeneWiki; MAPK11; -.
DR   GenomeRNAi; 5600; -.
DR   PRO; PR:Q15759; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000185386; -.
DR   CleanEx; HS_MAPK11; -.
DR   ExpressionAtlas; Q15759; baseline and differential.
DR   Genevisible; Q15759; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0098586; P:cellular response to virus; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0060044; P:negative regulation of cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:2001184; P:positive regulation of interleukin-12 secretion; IMP:UniProtKB.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:0051090; P:regulation of sequence-specific DNA binding transcription factor activity; TAS:Reactome.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008352; MAPK_p38.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01773; P38MAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Stress response; Transcription; Transcription regulation; Transferase.
FT   CHAIN         1    364       Mitogen-activated protein kinase 11.
FT                                /FTId=PRO_0000186280.
FT   DOMAIN       24    308       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      30     38       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      106    110       Inhibitor-binding.
FT   REGION      168    169       Inhibitor-binding.
FT   MOTIF       180    182       TXY.
FT   ACT_SITE    150    150       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      53     53       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      71     71       Nilotinib.
FT   MOD_RES     180    180       Phosphothreonine; by MAP2K3, MAP2K4 and
FT                                MAP2K6. {ECO:0000305|PubMed:15356147}.
FT   MOD_RES     182    182       Phosphotyrosine; by MAP2K3, MAP2K4 and
FT                                MAP2K6. {ECO:0000305|PubMed:15356147}.
FT   MOD_RES     323    323       Phosphotyrosine; by ZAP70. {ECO:0000250}.
FT   VAR_SEQ       1    108       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055221.
FT   VAR_SEQ     204    321       VDIWSVGCIMAELLQGKALFPGSDYIDQLKRIMEVVGTPSP
FT                                EVLAKISSEHARTYIQSLPPMPQKDLSSIFRGANPLAIDLL
FT                                GRMLVLDSDQRVSAAEALAHAYFSQYHDPEDEPEAE -> G
FT                                AGGRPWGDEGQGPRLALDWLCMPGLRGQARSPRMWDPHSKV
FT                                ALQRPLEHDGCWPPLAVQLWTSPCLGGLGMAEEGVCPSWGL
FT                                DVTVGLLEEGRGVGTLMEVPSPSHSGYLVRGLHHG (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055222.
FT   VAR_SEQ     322    364       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055223.
FT   VARIANT     221    221       A -> V (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042264.
FT   VARIANT     275    275       R -> H (in dbSNP:rs33932986).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.9}.
FT                                /FTId=VAR_025176.
FT   MUTAGEN     180    180       T->A: Inactivation.
FT   MUTAGEN     182    182       Y->F: Inactivation.
FT   CONFLICT     98     98       D -> V (in Ref. 8; BAF84534).
FT                                {ECO:0000305}.
FT   CONFLICT    122    123       LS -> GAHQGARLAL (in Ref. 1; AAB05036).
FT                                {ECO:0000305}.
FT   CONFLICT    326    326       S -> G (in Ref. 6; AAB66313).
FT                                {ECO:0000305}.
FT   STRAND        8     15       {ECO:0000244|PDB:3GP0}.
FT   STRAND       17     21       {ECO:0000244|PDB:3GP0}.
FT   STRAND       24     29       {ECO:0000244|PDB:3GP0}.
FT   STRAND       31     33       {ECO:0000244|PDB:3GC8}.
FT   TURN         34     37       {ECO:0000244|PDB:3GC9}.
FT   STRAND       38     43       {ECO:0000244|PDB:3GP0}.
FT   TURN         44     47       {ECO:0000244|PDB:3GP0}.
FT   STRAND       48     54       {ECO:0000244|PDB:3GP0}.
FT   HELIX        62     77       {ECO:0000244|PDB:3GP0}.
FT   STRAND       86     90       {ECO:0000244|PDB:3GP0}.
FT   HELIX        96     98       {ECO:0000244|PDB:3GP0}.
FT   STRAND      103    107       {ECO:0000244|PDB:3GP0}.
FT   STRAND      110    112       {ECO:0000244|PDB:3GP0}.
FT   HELIX       113    119       {ECO:0000244|PDB:3GP0}.
FT   HELIX       124    143       {ECO:0000244|PDB:3GP0}.
FT   HELIX       153    155       {ECO:0000244|PDB:3GP0}.
FT   STRAND      156    158       {ECO:0000244|PDB:3GP0}.
FT   STRAND      164    166       {ECO:0000244|PDB:3GP0}.
FT   HELIX       179    182       {ECO:0000244|PDB:3GC8}.
FT   HELIX       185    188       {ECO:0000244|PDB:3GP0}.
FT   HELIX       191    194       {ECO:0000244|PDB:3GP0}.
FT   HELIX       203    218       {ECO:0000244|PDB:3GP0}.
FT   HELIX       228    239       {ECO:0000244|PDB:3GP0}.
FT   HELIX       244    249       {ECO:0000244|PDB:3GP0}.
FT   TURN        253    255       {ECO:0000244|PDB:3GP0}.
FT   HELIX       256    260       {ECO:0000244|PDB:3GP0}.
FT   HELIX       270    273       {ECO:0000244|PDB:3GP0}.
FT   TURN        274    276       {ECO:0000244|PDB:3GC8}.
FT   HELIX       279    285       {ECO:0000244|PDB:3GP0}.
FT   TURN        286    288       {ECO:0000244|PDB:3GP0}.
FT   HELIX       293    295       {ECO:0000244|PDB:3GP0}.
FT   HELIX       299    302       {ECO:0000244|PDB:3GP0}.
FT   HELIX       306    308       {ECO:0000244|PDB:3GP0}.
FT   TURN        309    311       {ECO:0000244|PDB:3GP0}.
FT   HELIX       314    316       {ECO:0000244|PDB:3GP0}.
FT   HELIX       326    329       {ECO:0000244|PDB:3GP0}.
FT   HELIX       334    347       {ECO:0000244|PDB:3GP0}.
SQ   SEQUENCE   364 AA;  41357 MW;  68DA4C7B7C721475 CRC64;
     MSGPRAGFYR QELNKTVWEV PQRLQGLRPV GSGAYGSVCS AYDARLRQKV AVKKLSRPFQ
     SLIHARRTYR ELRLLKHLKH ENVIGLLDVF TPATSIEDFS EVYLVTTLMG ADLNNIVKCQ
     ALSDEHVQFL VYQLLRGLKY IHSAGIIHRD LKPSNVAVNE DCELRILDFG LARQADEEMT
     GYVATRWYRA PEIMLNWMHY NQTVDIWSVG CIMAELLQGK ALFPGSDYID QLKRIMEVVG
     TPSPEVLAKI SSEHARTYIQ SLPPMPQKDL SSIFRGANPL AIDLLGRMLV LDSDQRVSAA
     EALAHAYFSQ YHDPEDEPEA EPYDESVEAK ERTLEEWKEL TYQEVLSFKP PEPPKPPGSL
     EIEQ
//
